MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Hypercholesterolemia

Treatments: Drug: Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks; Drug: Comparator : niacin / Duraton of Treatment: 4 Weeks; Drug: MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00533312

0524A-026

2007_619

Details and patient eligibility

About

A study to determine lipid changing effects of MK0524A when compared to niacin extended release (NIASPAN) and placebo.

Enrollment: 407 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must be between the ages of 18 and 70 years
• Female patients must be pre-menopausal women that have been surgically sterilized, not pregnant and/or not planning to become pregnant

Exclusion criteria

• Patient has a history of peptic ulcer or gout
• Patient is sensitive to niacin or products containing niacin
• Patient drinks more than 2 alcoholic drinks per day
• Patient has certain heart disease, cancer, or is HIV positive

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind